Active transcription in the vascular bed characterizes rapid progression in idiopathic pulmonary fibrosis

Louise Hecker, Emory University
NS Sharma, Brigham and Women's Hospital
K Patel, University of South Florida, Tampa
E Sari, The University of Alabama at Birmingham
S Shankar, University of South Florida, Tampa
MG Gastanadui, The University of Alabama at Birmingham
D Moncada-Giraldo, Emory University
Y Soto-Vazquez, The University of Alabama at Birmingham
D Stacks, The University of Alabama at Birmingham
K Dsouza, The University of Alabama at Birmingham

Only first 10 authors above; see publication for full author list.

Journal Title: Journal of Clinical Investigation
Volume: Volume 133, Number 16
Publisher: (publisher) | 2023-08-15
Type of Work: Article
Publisher DOI: 10.1172/JCI165976
Permanent URL: https://pid.emory.edu/ark:/25593/w8fb5

Final published version: http://dx.doi.org/10.1172/JCI165976
Accessed October 19, 2023 12:49 PM EDT
To the Editor: Idiopathic pulmonary fibrosis (IPF) is the most common manifestation of interstitial lung disease, with a median survival of 3–5 years after diagnosis. IPF is characterized by progressive fibrosis with the development of fibroblastic foci in the interstitium. Despite the short median survival, there is a striking variance in the clinical course of IPF, with some patients characterized as stable progressors (SP) and some as rapid progressors (RP) based on their decline in lung function and loss of forced vital capacity (FVC) (1). While the presence of these two patient groups is well known, the biological mechanisms defining this dichotomy are poorly understood.

To investigate these differences, we collected lung biopsies from patients with IPF at the time of diagnosis and followed their disease progression (IRB PRO0032158, Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/JCI165976DS1). We identified 5 SP and 4 RP at the time of diagnosis based on loss of at least 10% FVC within the first year as well as 3 patients with terminal-stage IPF delineated for transplant (TP) and 3 individuals with age-matched normal lung tissues (NC) (clear margins from excision for pulmonary hamartoma). We investigated the presence of key transcriptional signatures using spatial transcriptomics (2). Briefly, sequential cuts of lung biopsies were stained with Trichrome or H&E and immunofluorescently labeled to identify nuclei, fibroblasts (α smooth muscle actin [αSMA]), and the vascular bed (CD31). Using a combination of H&E and immunofluorescent staining, regions of interest (ROIs) were selected for transcriptional analysis (see Supplemental Methods).

First, we sought to investigate whether transcriptional signatures of ROIs showing key features of IPF (collagen deposition and presence of fibroblastic foci) were sufficient to discriminate between SP and RP (Figure 1, A and B). SP samples showed increased expression of immunoglobulin genes (Figure 1C), while RP samples had increased expression of surfactant proteins A1, A2, and C, for which genetic variants have been associated with poor survival of 3–5 years after diagnosis. IPF is characterized by progressive fibrosis with the development of fibroblastic foci in the interstitium. Despite the short median survival, there is a striking variance in the clinical course of IPF, with some patients characterized as stable progressors (SP) and some as rapid progressors (RP) based on their decline in lung function and loss of forced vital capacity (FVC) (1). While the presence of these two patient groups is well known, the biological mechanisms defining this dichotomy are poorly understood.

To investigate these differences, we collected lung biopsies from patients with IPF at the time of diagnosis and followed their disease progression (IRB PRO0032158, Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/JCI165976DS1). We identified 5 SP and 4 RP at the time of diagnosis based on loss of at least 10% FVC within the first year as well as 3 patients with terminal-stage IPF delineated for transplant (TP) and 3 individuals with age-matched normal lung tissues (NC) (clear margins from excision for pulmonary hamartoma). We investigated the presence of key transcriptional signatures using spatial transcriptomics (2). Briefly, sequential cuts of lung biopsies were stained with Trichrome or H&E and immunofluorescently labeled to identify nuclei, fibroblasts (α smooth muscle actin [αSMA]), and the vascular bed (CD31). Using a combination of H&E and immunofluorescent staining, regions of interest (ROIs) were selected for transcriptional analysis (see Supplemental Methods).

First, we sought to investigate whether transcriptional signatures of ROIs showing key features of IPF (collagen deposition and presence of fibroblastic foci) were sufficient to discriminate between SP and RP (Figure 1, A and B). SP samples showed increased expression of immunoglobulin genes (Figure 1C), while RP samples had increased expression of surfactant proteins A1, A2, and C, for which genetic variants have been associated with poor prognosis in patients with IPF (3). Furthermore, CCNJ, a protein expressed in fibroblasts at homeostasis and highly induced in dysregulated fibrosis (4), was found to be significantly increased in RP.

While these differences were present in the overall transcriptome, they were not fully reflected in the specific cell populations (Supplemental Figure 1A), prompting a closer analysis of the different cell types. Unlike the general areas and the fibroblastic foci (Supplemental Figure 1, B–D), the vasculature in the RP samples (Figure 1D) was more transcriptionally active, with an increased proportion of differentially expressed genes compared with SP and TP samples (Figure 1, E–G, and Supplemental Figure 1, E–G), but similarly active compared with NC samples (73 upregulated genes in NC and 70 in RP), suggesting a potentially novel avenue to investigate the role of pulmonary vasculature in the progression of IPF. At the transcriptional level, upregulated genes in the RP vascular bed, compared with that of SP, TP, and NC, including LRRC38, LUM, COAS, and ITM2A, were mainly under the control of TBX3 (Supplemental Figure 1H), a member of a transcription factor family overexpressed in models of lung fibrosis (5) (Figure 1H and Supplemental Figure 1I). These differences were also corroborated by comparison with publicly available single-cell RNA-Seq data sets that included endothelial cells (http://www.ipfcellatlas.com/) (Supplemental Table 2), and TBX3 expression at the protein level was confirmed by immunofluorescence (Supplemental Figure 1J).

Given the increased transcriptional activity found in the vasculature of the RP group, we investigated whether there could be transcriptional crosstalk between the vascular bed and the fibroblastic foci. In the fibroblastic foci (Supplemental Figure 1D), distinct HLA-DQ haplotypes were expressed in the SP and RP groups, suggesting differential immune responses in the two groups. Furthermore, MMP7 was highly expressed in the RP group compared with that in the SP and TP groups (Supplemental Figure 1, D and I), strengthening its role as a biomarker for rapid FVC decline. The role of MMP7 in the reorganization of the extracellular matrix is well known. However, MMP7 can serve as a crosstalk mediator between the secreting cells and the endothelium. Indeed, MMP7 indirectly promotes angiogenesis via the cleavage of the soluble VEGF receptor 1, and the cleavage of CCN2, resulting in the increased bioavailability of VEGF and reactivation of its angiogenic activity (6). While our data suggest a crosstalk between fibroblasts and the vascular bed, future studies will be needed to better understand other targets and interactions between cell types involved in lung fibrosis, including the effect of VEGF in the interaction among the capillary endothelial cells, the epithelium, and the inflammatory cells.

In conclusion, this study suggests a key role of the vascular bed in the progression of IPF, warranting further investigations. This study has limitations owing to its preliminary nature; use of a large control group with minimal lung disease would allow for statistically robust multivariate analysis in future larger studies. Furthermore, these results show similarities with publicly available single-cell transcriptional data sets, and they also highlight key differences. These could be attributed either to technical aspects of transcriptional profiling or selection of specific IPF subphenotypes. Future studies with a controlled patient cohort will be needed to discern the true variability between gene profiling by single-cell RNA-Seq and spatial transcriptomics. Nevertheless, these data highlight distinct pathways of crosstalk between fibroblasts and the vascular bed, which could prove central to the pathophysiology of the disease. Targeting such pathways and modulating the interaction between the vasculature and fibroblasts may usher the development of future therapeutics to limit the progression of IPF.

Acknowledgments
This work was supported by NIH grant 1R01HL161620-01 (to NSS), OTA-21-015E (to AG), and 1R01HL126596 (to AG); Veterans Administration grant 101CX001969 (to AG); and Cystic Fibrosis Foundation grant MARGAR21F5 (to CM).
Nirmal S. Sharma,1,2 Kapil Patel,3 Ezgi Sari,4 Shruti Shankar,3 Maria G. Gastanadui,4 Diego Moncada-Giraldo,5 Yixel Soto-Vazquez,4 Delores Stacks,4 Louise Hecker,7 Kevin Dsouza,4 Edward O’Neill,3 Paul Benson,6 Gregory Payne,4,8,9 Camilla Margaroli,4,6 and Amit Gaggar4,8,9

1Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA. 2West Roxbury VA Medical Center, Boston, Massachusetts, USA. 3Department of Medicine, University of South Florida, Tampa, Florida, USA. 4Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA. 5Department of Pediatrics, Emory University, Atlanta, Georgia, USA. 6Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA. 7Department of Medicine, Emory University, Atlanta, Georgia, USA. 8Birmingham VA Medical Center, Birmingham, Alabama, USA. 9Lung Health Center, Program in Protease and Matrix Biology, and Gregory Fleming James CF Center, University of Alabama at Birmingham, Birmingham, Alabama, USA.


Address correspondence to: Amit Gaggar, Bevill Biomedical Research Building, 845 19th St S, Rm 810, Birmingham, Alabama 35294, USA. Phone: 205.934.4304; Email: agaggar@uabmc.edu.